ArticleProtein engineering, design & selection : PEDS2010
ImmunoPET imaging of B-cell lymphoma using 124I-anti-CD20 scFv dimers (diabodies).
Article in Protein engineering, design & selection : PEDS, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Reengineered Anti-CD4 Cys-diabody Variants forMolecular imaging and biology · 2025Article
- Novel PET Imaging of Inflammatory Targets and Cells for the Diagnosis and Monitoring of Giant Cell Arteritis and Polymyalgia Rheumatica.Frontiers in medicine · 2022Review
- Radiochemistry, Production Processes, Labeling Methods, and ImmunoPET Imaging Pharmaceuticals of Iodine-124.Molecules (Basel, Switzerland) · 2021Review
- Antibody Fragment and Affibody ImmunoPET Imaging Agents: Radiolabelling Strategies and Applications.ChemMedChem · 2018Review
- The Immunoimaging Toolbox.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2018Review
- ImmunoPET of Malignant and Normal B Cells withClinical cancer research : an official journal of the American Association for Cancer Research · 2017Article
- Lymphoma: current status of clinical and preclinical imaging with radiolabeled antibodies.European journal of nuclear medicine and molecular imaging · 2017Review
- Fluorescent Image-Guided Surgery with an Anti-Prostate Stem Cell Antigen (PSCA) Diabody Enables Targeted Resection of Mouse Prostate Cancer Xenografts in Real Time.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016Article
- Radiation Dosimetry Study of [(89)Zr]rituximab Tracer for Clinical Translation of B cell NHL Imaging using Positron Emission Tomography.Molecular imaging and biology · 2015Article
- Article
- Near-infrared fluorescence imaging of non-Hodgkin's lymphoma CD20 expression using Cy7-conjugated obinutuzumab.Molecular imaging and biology · 2014Article
- Enhanced immunoPET of ALCAM-positive colorectal carcinoma using site-specific ⁶⁴Cu-DOTA conjugation.Protein engineering, design & selection : PEDS · 2014Article
- Development, optimization, and validation of novel anti-TEM1/CD248 affinity agent for optical imaging in cancer.Oncotarget · 2014Article
- Engineered antibody fragments for immuno-PET imaging of endogenous CD8+ T cells in vivo.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
- Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2012Article
- Positron emission tomography of 64Cu-DOTA-Rituximab in a transgenic mouse model expressing human CD20 for clinical translation to image NHL.Molecular imaging and biology · 2012Article
- Analysis of the relationship between end-to-end distance and activity of single-chain antibody against colorectal carcinoma.Theoretical biology & medical modelling · 2012Article
- Anti-carcinoembryonic antigen single-chain variable fragment antibody variants bind mouse and human neonatal Fc receptor with different affinities that reveal distinct cross-species differences in serum half-life.The Journal of biological chemistry · 2012Article
- ImmunoPET using engineered antibody fragments: fluorine-18 labeled diabodies for same-day imaging.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2012Article
- Bioinformatics-led design of single-chain antibody molecules targeting DNA sequences for retinoblastoma.International journal of ophthalmology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Rapid clearing engineered antibody fragments for immunoPET promise high sensitivity at early time points. Here, tumor targeting of anti-CD20 diabodies (scFv dimers) for detection of low-grade B-cell lymphomas were evaluated. In addition, the effect of linker length on oligomerization of the diabody was investigated. Four rituximab scFv variants in the V(L)-V(H) orientation with different linker lengths between the V domains (scFv-1, scFv-3, scFv-5, scFv-8), plus the scFv-5 with a C-terminal cysteine (Cys-Db) for site-specific modification were generated. The scFv-8 and Cys-Db were radioiodinated with (124)I for PET imaging, and biodistribution of (131)I-Cys-Db was carried out at 2, 4 10 and 20 h. The five anti-CD20 scFv variants were expressed as fully functional dimers. Shortening the linker to three or one residue did not produce higher order of multimers. Both (124)I-labeled scFv-8 and Cys-Db exhibited similar tumor targeting at 8 h post injection, with significantly higher uptakes than in control tumors (P < 0.05). At 20 h, less than 1% ID/g of (131)I-labeled Cys-Db was present in tumors and tissues. Specific tumor targeting and high contrast images were achieved with the anti-CD20 diabodies. These agents extend the repertoire of reagents that can potentially be used to improve detection of low-grade lymphomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.